Physician profile
Jason Smith
NPI 1407937899
$6,240.21
in general payments reported to CMS, 2019-2025
43 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.61 · 2020: $352 · 2021: $533 · 2022: $317 · 2023: $531 · 2024: $3,897 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,773 · Travel and Lodging: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.06 |
| Travel and Lodging | $216.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $3,066.67 | 2024 | Watchpatone |
| Lilly USA, LLC | $371.48 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $310.92 | 2022-2025 | |
| Pfizer INC. | $225.84 | 2019-2025 | |
| Intuitive Surgical, INC. | $216.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $199.30 | 2020-2023 | Spravato |
| Novo Nordisk INC | $189.54 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.97 | 2020-2025 | Jardiance, Ofev, Synjardy |
| Sanofi-Aventis U.S. LLC | $123.95 | 2025 | |
| Merck Sharp & Dohme LLC | $118.38 | 2020-2024 | Belsomra, Verquvo, Lagevrio |
| Glaxosmithkline, LLC. | $105.43 | 2023-2025 | Shingrix, Arexvy |
| Abbvie INC. | $101.48 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.08 | 2020-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $76.98 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $65.13 | 2023-2024 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.